Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

NCT06863376 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: Carbocysteine 375 MG
OTHER: Physical activity, walking, and calorie restriction

Sponsor

Tanta University